Figure 2
From: The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent
TLR8 protein expression is associated with HNSCC patient survival. (A) Representative examples of TLR8 immunostaining and expression scores in HNSCCs. (B) Kaplan–Meier estimates of overall survival according to TLR8 expression score(s). (C, D) Kaplan–Meier estimates of overall survival according to TLR8 expression score(s) in low EGFR-expressing (C) and high EGFR-expressing (D) HNSCCs. (E) Representative examples of CD8 immunostaining and expression scores in HNSCCs from (A). F: Percentage of tumors with high, moderate or low CD8 immunostaining based on TLR8 expression scores. G: Percentage of tumors with high, moderate or low CD8 immunostaining based on TLR8 + EGFR expression. IR: immunoreactivity. *p < 0.05, ****p < 0.0001, n.s.-non-significant (Fisher’s exact test).
